GC
NBIX icon

Globeflex Capital’s Neurocrine Biosciences NBIX Stock Holding History

Globeflex Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.78M Buy
28,363
+190
+0.7% +$28.2K 0.61% 52
2026
Q1 		$3.71M Sell
28,173
-1,341
-5% -$178K 0.56% 57
2025
Q4 		$4.19M Hold
29,514
– – 0.64% 53
2025
Q3 		$4.14M Buy
29,514
+1,057
+4% +$143K 0.64% 51
2025
Q2 		$3.58M Buy
28,457
+6,255
+28% +$717K 0.3% 78
2025
Q1 		$2.46M Sell
22,202
-1,202
-5% -$152K 0.23% 94
2024
Q4 		$3.19M Buy
23,404
+1,202
+5% +$149K 0.27% 87
2024
Q3 		$2.56M Buy
22,202
+703
+3% +$96.4K 0.25% 93
2024
Q2 		$2.96M Sell
21,499
-1,437
-6% -$197K 0.31% 73
2024
Q1 		$3.16M Hold
22,936
– – 0.31% 75
2023
Q4 		$3.02M Buy
22,936
+1,781
+8% +$205K 0.31% 80
2023
Q3 		$2.38M Hold
21,155
– – 0.28% 97
2023
Q2 		$1.99M Sell
21,155
-3,911
-16% -$382K 0.22% 116
2023
Q1 		$2.54M Buy
25,066
+7,828
+45% +$815K 0.31% 90
2022
Q4 		$2.06M Buy
17,238
+5,708
+50% +$669K 0.26% 97
2022
Q3 		$1.23M Buy
+11,530
New +$1.17M 0.21% 147
2020
Q4 		– Sell
-5,632
Closed -$542K – 505
2020
Q3 		$542K Sell
5,632
-999
-15% -$116K 0.14% 237
2020
Q2 		$809K Sell
6,631
-2,637
-28% -$291K 0.21% 168
2020
Q1 		$802K Hold
9,268
– – 0.25% 144
2019
Q4 		$996K Buy
+9,268
New +$970K 0.19% 192
2015
Q4 		– Sell
-20,400
Closed -$812K – 485
2015
Q3 		$812K Sell
20,400
-4,000
-16% -$193K 0.17% 211
2015
Q2 		$1.17M Buy
+24,400
New +$1.03M 0.21% 178

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Globeflex Capital's NBIX Position: Q2 2026 in Review

Globeflex Capital increased its Neurocrine Biosciences (NBIX) stake by 0.67% in Q2 2026, buying an estimated $28.2K and bringing the position to 28,363 shares worth $4.78M. The position accounts for 0.61% of the portfolio, ranked #52.

Globeflex Capital first reported a position in NBIX in Q2 2015 and has held it in 22 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Globeflex Capital held 28,363 shares of Neurocrine Biosciences worth $4.78M as of Q2 2026.
  • Globeflex Capital bought 190 Neurocrine Biosciences shares in Q2 2026, an estimated $28.2K.
  • Neurocrine Biosciences made up 0.61% of Globeflex Capital's portfolio in Q2 2026, its #52 holding.
  • Globeflex Capital first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 22 quarters since.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.